{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T09:11:09.892873+00:00","company":{"ticker":"IMNN","cik":749647,"company_name":"Imunon, Inc."},"pagination":{"limit":100,"returned":46,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Streeterville Capital, LLC","detail":"equity_purchase","count":1,"first_seen":"2026-06-04T12:00:40+00:00","last_seen":"2026-06-04T12:00:40+00:00","evidence_fact_ids":[65971]},{"display_name":"a single healthcare-focused institutional investor","detail":"equity_purchase","count":1,"first_seen":"2025-12-31T23:59:59+00:00","last_seen":"2025-12-31T23:59:59+00:00","evidence_fact_ids":[36601]}],"lender":[{"display_name":"Streeterville Capital, LLC","detail":"other","count":2,"first_seen":"2026-06-04T12:00:40+00:00","last_seen":"2026-06-04T12:00:40+00:00","evidence_fact_ids":[65973,65974]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"6f25c0aef433c66c866ac8b881653942820bb66f","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-06-16T21:30:17+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of amendment to IMUNON, INC. 2018 Stock Incentive Plan to increase aggregate share limit","proposal_type":"equity_plan","results":[{"broker_non_votes":"1,090,375","subject":null,"votes_abstain":"18,614","votes_against":"137,055","votes_for":"562,622","votes_withheld":null}]},"claim":"Imunon, Inc. shareholders approved Approval of amendment to IMUNON, INC. 2018 Stock Incentive Plan to increase aggregate share limit.","evidence_excerpt":"The proposal to approve an Amendment to the IMUNON, INC. 2018 Stock Incentive Plan to increase the aggregate number of shares of common stock that may be delivered pursuant to all awards granted under the Plan was approved based upon the following votes: For Against Abstain Broker Non-Votes 562,622 137,055 18,614 1,090,375","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-028937","anchor_url":"https://secwatch.observer/filing/0001493152-26-028937#claim-6f25c0aef433c66c866ac8b881653942820bb66f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226028937/0001493152-26-028937-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3e8f44230616ac42111e867b7a7b49a75476fd52","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-06-16T21:30:17+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Advisory vote to approve 2025 compensation of named executive officers (Say-on-Pay)","proposal_type":"say_on_pay","results":[{"broker_non_votes":"1,090,375","subject":null,"votes_abstain":"22,529","votes_against":"115,666","votes_for":"580,096","votes_withheld":null}]},"claim":"Imunon, Inc. shareholders approved Advisory vote to approve 2025 compensation of named executive officers (Say-on-Pay).","evidence_excerpt":"The proposal to approve, on an advisory basis, the 2025 compensation of the Company's named executive officers (“Say-on-Pay”), was approved based upon the following votes: For Against Abstain Broker Non-Votes 580,096 115,666 22,529 1,090,375","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-028937","anchor_url":"https://secwatch.observer/filing/0001493152-26-028937#claim-3e8f44230616ac42111e867b7a7b49a75476fd52","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226028937/0001493152-26-028937-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2ab3398506bc083342f168648ec9079a8fa657f0","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-06-16T21:30:17+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-12-31","outcome":"passed","proposal_text":"Ratification of appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"11,386","votes_against":"81,399","votes_for":"1,715,881","votes_withheld":null}]},"claim":"Imunon, Inc. shareholders approved Ratification of appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year 2026 at the 2026-12-31 meeting.","evidence_excerpt":"The Company's stockholders ratified the appointment of WithumSmith + Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows: For Against Abstain 1,715,881 81,399 11,386","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-028937","anchor_url":"https://secwatch.observer/filing/0001493152-26-028937#claim-2ab3398506bc083342f168648ec9079a8fa657f0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226028937/0001493152-26-028937-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d2b23bd6ba59a931c4bae46c68ae15e8d7399569","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-06-16T21:30:17+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of Class I directors to serve until the 2029 annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"1,090,375","subject":"Mr. Frederick J. Fritz","votes_abstain":null,"votes_against":null,"votes_for":"647,890","votes_withheld":"70,401"},{"broker_non_votes":"1,090,375","subject":"Ms. Christine A. Pellizzari","votes_abstain":null,"votes_against":null,"votes_for":"653,302","votes_withheld":"64,989"}]},"claim":"Imunon, Inc. shareholders approved Election of Class I directors to serve until the 2029 annual meeting.","evidence_excerpt":"The Company's stockholders elected the individuals listed below as Class I directors of the Company's board of directors until the Company's 2029 annual meeting of stockholders. The results of the vote were as follows: Nominee For Withheld Broker Non-Votes Mr. Frederick J. Fritz 647,890 70,401 1,090,375 Ms. Christine A. Pellizzari 653,302 64,989 1,090,375","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-028937","anchor_url":"https://secwatch.observer/filing/0001493152-26-028937#claim-d2b23bd6ba59a931c4bae46c68ae15e8d7399569","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226028937/0001493152-26-028937-index.htm"},{"fact_type":"governance_change","fact_key":"59723d2ee4f5fc8b1e9eb85bf94b52e61c8e9d20","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-06-04T12:00:40+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-06-01","item_codes_triggered":["5.03"],"summary_text":"Filed a Certificate of Designation for Series A Preferred Stock designating 400 shares"},"claim":"Imunon, Inc.: Filed a Certificate of Designation for Series A Preferred Stock designating 400 shares (effective 2026-06-01).","evidence_excerpt":"On June 1, 2026, the Company filed a certificate of designation of preferences and rights (the “ Certificate of Designation ”) of the Series A Preferred Stock with the Secretary of State of the State of Delaware, designating 400 shares of Series A Preferred Stock, which became effective upon filing.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-027201","anchor_url":"https://secwatch.observer/filing/0001493152-26-027201#claim-59723d2ee4f5fc8b1e9eb85bf94b52e61c8e9d20","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/0001493152-26-027201-index.htm"},{"fact_type":"debt_financing","fact_key":"2f52e7d33a1cf971cf3e85ff26e2154ee60503dc","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-06-04T12:00:40+00:00","payload":{"counterparty":"Streeterville Capital, LLC","effective_date":"2026-06-03","event":"incurrence","instrument_type":"other","interest_rate_text":"5% per annum","item_codes_triggered":["2.03"],"maturity_text":"18 months following the Closing Date","principal_text":"$5,000,000"},"claim":"Imunon, Inc. incurred debt of $5,000,000 with Streeterville Capital, LLC at 5% per annum maturing 18 months following the Closing Date.","evidence_excerpt":"(ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the\n“ A-1 Note ”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “ B\nNote ” and together with the A-1 Note, the “ Notes ”). The transactions contemplated by the Securities\nPurchase Agreement (collectively, the “ Transaction ”) closed on","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-027201","anchor_url":"https://secwatch.observer/filing/0001493152-26-027201#claim-2f52e7d33a1cf971cf3e85ff26e2154ee60503dc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/0001493152-26-027201-index.htm"},{"fact_type":"debt_financing","fact_key":"88d4952ff7d77a87b05533508fa1b426de092a0e","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-06-04T12:00:40+00:00","payload":{"counterparty":"Streeterville Capital, LLC","effective_date":"2026-06-03","event":"incurrence","instrument_type":"other","interest_rate_text":"8% per annum","item_codes_triggered":["2.03"],"maturity_text":"18 months following the Closing Date","principal_text":"$2,720,000"},"claim":"Imunon, Inc. incurred debt of $2,720,000 with Streeterville Capital, LLC at 8% per annum maturing 18 months following the Closing Date.","evidence_excerpt":"(the “ Series A Preferred Stock ”), at a price of $10,000\nper share, for aggregate proceeds of $2,500,000; (ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the\n“ A-1 Note ”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “ B\nNote ” and together with the A-1 Note, the “ Notes ”). The","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-027201","anchor_url":"https://secwatch.observer/filing/0001493152-26-027201#claim-88d4952ff7d77a87b05533508fa1b426de092a0e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/0001493152-26-027201-index.htm"},{"fact_type":"material_agreement","fact_key":"af5b1008739b1c5f48db29487de480e66c7a15ed","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-06-04T12:00:40+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Streeterville Capital, LLC","effective_date":"2026-06-02","item_codes_triggered":["1.01"],"value_text":"Total financing of $10,000,000; issuance of 250 shares of Series A Preferred Stock at $10,000 per sh"},"claim":"Imunon, Inc. entered into Securities Purchase Agreement with Streeterville Capital, LLC valued at Total financing of $10,000,000; issuance of 250 shares of Series A Preferred Stock at $10,000 per sh (effective 2026-06-02).","evidence_excerpt":"On June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) 250 shares (the “ Preferred Shares ”) of the Company’s Series A Preferred Stock, par value $0.01 per share (the “ Series A Preferred Stock ”), at a price of $10,000 per share, for aggregate proceeds of $2,500,000; (ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the “ A-1 Note ”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “ B Note ” and together with the A-1 Note, the “ Notes ”).","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001493152-26-027201","anchor_url":"https://secwatch.observer/filing/0001493152-26-027201#claim-af5b1008739b1c5f48db29487de480e66c7a15ed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226027201/0001493152-26-027201-index.htm"},{"fact_type":"earnings_release","fact_key":"edf0d031270e1566fb79286a90f891e8106f3f6e","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-05-12T12:05:36+00:00","payload":{"eps_text":"$0.84 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$4.3 million","period_text":"the three months ended March 31, 2026","report_date":"2026-05-12","result_type":"reported_results","revenue_text":null},"claim":"Imunon, Inc. reported the three months ended March 31, 2026 results: net income $4.3 million, EPS $0.84 per share.","evidence_excerpt":"Net loss for the first quarter of 2026 was $4.3 million, or $0.84 per share","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-26-022401","anchor_url":"https://secwatch.observer/filing/0001493152-26-022401#claim-edf0d031270e1566fb79286a90f891e8106f3f6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226022401/0001493152-26-022401-index.htm"},{"fact_type":"earnings_release","fact_key":"f8c73ba33df04f0521a7fe2beea40595f352f855","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2026-03-31T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2025","report_date":"2026-03-31","result_type":"reported_results","revenue_text":null},"claim":"Imunon, Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2025","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001493152-26-013816","anchor_url":"https://secwatch.observer/filing/0001493152-26-013816#claim-f8c73ba33df04f0521a7fe2beea40595f352f855","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/0001493152-26-013816-index.htm"},{"fact_type":"material_agreement","fact_key":"1cb7aa4125afdecb60e725ee119605499d0408ce","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-12-31T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"a single healthcare-focused institutional investor","effective_date":"2025-12-29","item_codes_triggered":["1.01"],"value_text":"combined offering price of $3.61 per Share and Warrant"},"claim":"Imunon, Inc. entered into Securities Purchase Agreement with a single healthcare-focused institutional investor valued at combined offering price of $3.61 per Share and Warrant (effective 2025-12-29).","evidence_excerpt":"On December 29, 2025, Imunon, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused institutional investor (the “Purchaser”) for a registered direct offering","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-029711","anchor_url":"https://secwatch.observer/filing/0001493152-25-029711#claim-1cb7aa4125afdecb60e725ee119605499d0408ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315225029711/0001493152-25-029711-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"6a7430e1063d61f726e0fdddf5de18de4247daa5","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-08-28T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-27","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Imunon, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 27, 2025, Imunon, Inc. (the “Company”) received a written notification from the Nasdaq Hearings Panel indicating that\nthe Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital\nMarket pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-012417","anchor_url":"https://secwatch.observer/filing/0001493152-25-012417#claim-6a7430e1063d61f726e0fdddf5de18de4247daa5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/0001493152-25-012417-index.htm"},{"fact_type":"governance_change","fact_key":"9bdc9a937d1f562e2f06ec87a0b04bb485c1a97a","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-07-23T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-07-25","item_codes_triggered":["5.03"],"summary_text":"Amended Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split of common stock."},"claim":"Imunon, Inc.: Amended Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split of common stock (effective 2025-07-25).","evidence_excerpt":"On July 21, 2025, Imunon, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Restated Certificate of Incorporation (as amended to date, the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a one-for-fifteen (1-for-15) reverse stock split (the “Reverse Stock Split”) of its outstanding common stock, par value $0.01 per share (the “Common Stock”). The Reverse Stock Split will become effective on July 25, 2025 at 12:01 a.m. Eastern Time (the “Effective Time”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-020652","anchor_url":"https://secwatch.observer/filing/0001641172-25-020652#claim-9bdc9a937d1f562e2f06ec87a0b04bb485c1a97a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000164117225020652/0001641172-25-020652-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"8197e0f32717a831e4f65d43389ba0db096afd09","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-07-14T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-07-11","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5505(b), Nasdaq Listing Rule 5550(b)(1), Nasdaq Listing Rule 5810(d)(2)","reported_value":null,"rule_numbers":["5505(b)","5550(b)(1)","5810(d)(2)"],"rules_cited_in_text":true},"claim":"Imunon, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5505(b), 5550(b)(1), 5810(d)(2)).","evidence_excerpt":"July 11, 2025, the Panel notified the Company that it has granted Company’s request for an exception (the “Exception”)\ntailored to the time needed for the Company to regain compliance with the Minimum Bid Price Requirement and the Minimum Stockholders’\nEquity Requirement. Pursuant\nto the Exception, the Company is required to provide the Panel with prompt notification of any significant events that occur, including\nany event that may call into question the Company’s ability to satisfy the terms of the Exception. There\ncan be no assurance that the Company will be able to regain compliance with t","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-019541","anchor_url":"https://secwatch.observer/filing/0001641172-25-019541#claim-8197e0f32717a831e4f65d43389ba0db096afd09","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000164117225019541/0001641172-25-019541-index.htm"},{"fact_type":"governance_change","fact_key":"b710a567ab000aaf98ecb040af5e476548a32db9","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-07-11T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-07-11","item_codes_triggered":["5.03"],"summary_text":"Approved amendment to Restated Certificate of Incorporation to increase authorized common shares from 112,500,000 to 350,000,000 and make corresponding change to authorized capital stock."},"claim":"Imunon, Inc.: Approved amendment to Restated Certificate of Incorporation to increase authorized common shares from 112,500,000 to 350,000,000 and make corresponding change to authorized capital stock (effective 2025-07-11).","evidence_excerpt":"the Company’s stockholders voted on and approved an amendment (the “Amendment”) to the Company’s Restated Certificate of Incorporation (the “Certificate of Incorporation”), to increase the number of authorized shares of common stock from 112,500,000 shares to 350,000,000 shares, and to make a corresponding change to the number of authorized shares of capital stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-018797","anchor_url":"https://secwatch.observer/filing/0001641172-25-018797#claim-b710a567ab000aaf98ecb040af5e476548a32db9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000164117225018797/0001641172-25-018797-index.htm"},{"fact_type":"executive_change","fact_key":"6003df3fab","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-06-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-13","interim":true,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Kimberly Graper was appointed as interim Chief Financial Officer at Imunon, Inc..","evidence_excerpt":"As a result of the termination of the Agreement and Mr. Gaiero’s related service, effective June 13, 2025, the Company appointed Kimberly Graper to serve as the Company’s interim Chief Financial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-015124","anchor_url":"https://secwatch.observer/filing/0001641172-25-015124#claim-6003df3fab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000164117225015124/0001641172-25-015124-index.htm"},{"fact_type":"executive_change","fact_key":"3660866ff2","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-06-13T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2025-06-13","interim":true,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":"Kimberly Graper","successor_named":true},"claim":"David Gaiero was terminated as interim Chief Financial Officer at Imunon, Inc..","evidence_excerpt":"On June 13, 2025, Imunon, Inc. (the “Company”) terminated the consulting agreement (as amended, the “Agreement”), dated April 15, 2024, by and between the Company and Monomoy Advisors, LLC, a financial advisory services firm (“Monomoy”), as well as David Gaiero’s service pursuant to the Agreement as the Company’s interim Chief Financial Officer (a position he has held since June of 2024), in each case effective June 13, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-015124","anchor_url":"https://secwatch.observer/filing/0001641172-25-015124#claim-3660866ff2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000164117225015124/0001641172-25-015124-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"ce27ee7200ea5f5a85aac420f428e17a82b00da0","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-05-30T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-05-28","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)","5505(b)","5550(b)(1)","5810(d)(2)"],"rules_cited_in_text":true},"claim":"Imunon, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5505(b), 5550(b)(1), 5810(d)(2)).","evidence_excerpt":"May 28, 2025 (the “Delisting Determination Letter”). As\npreviously reported, the Company received a deficiency letter on May 19, 2025 from the Staff notifying the Company that it is no longer\nin compliance with the minimum stockholders’ equity requirement (the “Minimum Stockholders’ Equity Requirement”)\nfor continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1). Pursuant to Nasdaq Listing Rule 5810(d)(2),\nthe failure to comply with the Minimum Stockholders’ Equity Requirement has individually become an additional and separate basis\nfor delisting. The\nDelistin","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001641172-25-013051","anchor_url":"https://secwatch.observer/filing/0001641172-25-013051#claim-ce27ee7200ea5f5a85aac420f428e17a82b00da0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000164117225013051/0001641172-25-013051-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"c810b61326662132922e222da300b75e7a9d6b54","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-05-30T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-11-26","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Imunon, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"November 26, 2024, Imunon, Inc. (“the Company”) received a letter from the staff (the “Staff”)\nof The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common\nstock, for the previous 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid\nprice of $1.00 per share (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market, as set\nforth in Nasdaq Listing Rule 5550(a)(2) (the “Original Notice”). At that time, the Company was provided a compliance period\nof 180 c","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001641172-25-013051","anchor_url":"https://secwatch.observer/filing/0001641172-25-013051#claim-c810b61326662132922e222da300b75e7a9d6b54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000164117225013051/0001641172-25-013051-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"60ed4026eba9a11b6006cd255bf3aa27a1a37d5e","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-05-20T23:59:59+00:00","payload":{"company_response":"The Company is currently evaluating options to regain compliance and intends to timely submit a plan.","compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$2,500,000","notice_date":"2025-05-19","notice_type":"deficiency_notice","plan_due_date":"2025-07-03","raw_rule_text":"Nasdaq Listing Rule 5550(b)(1)","reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Imunon, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 19, 2025, Imunon, Inc. (“the Company”) received a letter (the “Notice”) from the staff (the “Staff”)\nof The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is no longer in compliance with the minimum stockholders’\nequity requirement (the “Minimum Stockholders’ Equity Requirement”) for continued listing on The Nasdaq Capital Market\npursuant to Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’\nequity of at least $2,500,000 or meet the alternative compliance standards relating to the market value of listed securities or ne","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-011601","anchor_url":"https://secwatch.observer/filing/0001641172-25-011601#claim-60ed4026eba9a11b6006cd255bf3aa27a1a37d5e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000164117225011601/0001641172-25-011601-index.htm"},{"fact_type":"executive_change","fact_key":"6c520553ce","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2025-02-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-18","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Douglas Faller was appointed as Chief Medical Officer at Imunon, Inc..","evidence_excerpt":"On February 9, 2025, the Board of Directors of Imunon, Inc. (the “Company”) appointed Dr. Douglas Faller (age 72) as Chief Medical Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-25-005536","anchor_url":"https://secwatch.observer/filing/0001493152-25-005536#claim-6c520553ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/0001493152-25-005536-index.htm"},{"fact_type":"executive_change","fact_key":"7fb906f477","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2024-10-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-07","interim":false,"role":"General Counsel and Corporate Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Susan Eylward was appointed as General Counsel and Corporate Secretary at Imunon, Inc..","evidence_excerpt":"On October 4, 2024, the Board of Directors of Imunon, Inc. (the “Company”) appointed Susan Eylward (age 45) as General Counsel and Corporate Secretary.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-039646","anchor_url":"https://secwatch.observer/filing/0001493152-24-039646#claim-7fb906f477","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224039646/0001493152-24-039646-index.htm"},{"fact_type":"executive_change","fact_key":"7573818ba8","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2024-05-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"David Gaiero was appointed as Chief Financial Officer at Imunon, Inc..","evidence_excerpt":"effective June 1, 2024, the Company appointed David Gaiero to serve as the Company’s new Chief Financial Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-020543","anchor_url":"https://secwatch.observer/filing/0001493152-24-020543#claim-7573818ba8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/0001493152-24-020543-index.htm"},{"fact_type":"executive_change","fact_key":"1a5d201d35","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2024-05-20T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2024-06-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"David Gaiero","successor_named":true},"claim":"Jeffrey Church retired as Chief Financial Officer at Imunon, Inc..","evidence_excerpt":"On May 15, 2024, Jeffrey Church informed Imunon, Inc. (the “Company”) of his intent to retire from all positions with the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-020543","anchor_url":"https://secwatch.observer/filing/0001493152-24-020543#claim-1a5d201d35","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/0001493152-24-020543-index.htm"},{"fact_type":"earnings_release","fact_key":"8412bc7ebc3bef5d896a67dae89be7978ec1bc94","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":null},"claim":"Imunon, Inc. reported financial results for quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, Imunon, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-018791","anchor_url":"https://secwatch.observer/filing/0001493152-24-018791#claim-8412bc7ebc3bef5d896a67dae89be7978ec1bc94","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224018791/0001493152-24-018791-index.htm"},{"fact_type":"executive_change","fact_key":"a68a0119f0","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-13","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Stacy R. Lindborg was appointed as President and Chief Executive Officer at Imunon, Inc..","evidence_excerpt":"On May 8, 2024, Imunon, Inc. (the “Company”) announced the appointment of Stacy R. Lindborg, Ph.D., as President and Chief Executive Officer of the Company, effective as of May 13, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-018166","anchor_url":"https://secwatch.observer/filing/0001493152-24-018166#claim-a68a0119f0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224018166/0001493152-24-018166-index.htm"},{"fact_type":"governance_change","fact_key":"39f27a5aa60bb5b543376f0d0726f4b7f8846e40","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2024-03-18T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-03-15","item_codes_triggered":["5.03"],"summary_text":"Amended and Restated Bylaws to revise voting thresholds for stockholder approval and modify adjournment procedures for stockholder meetings to reflect DGCL amendments"},"claim":"Imunon, Inc.: Amended and Restated Bylaws to revise voting thresholds for stockholder approval and modify adjournment procedures for stockholder meetings to reflect DGCL amendments (effective 2024-03-15).","evidence_excerpt":"On March 15, 2024, in connection with certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Imunon, Inc. (the “ Company ”), the Company’s Board of Directors approved and adopted certain amendments to the Company’s bylaws (as amended to date, the “ Amended and Restated Bylaws ”), which became immediately effective.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-010195","anchor_url":"https://secwatch.observer/filing/0001493152-24-010195#claim-39f27a5aa60bb5b543376f0d0726f4b7f8846e40","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224010195/0001493152-24-010195-index.htm"},{"fact_type":"executive_change","fact_key":"5cd329b63d","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-03-15","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Corinne Le Goff resigned as President and Chief Executive Officer at Imunon, Inc..","evidence_excerpt":"On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the “Board”) of Imunon, Inc. (the “Company”) of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-009684","anchor_url":"https://secwatch.observer/filing/0001493152-24-009684#claim-5cd329b63d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224009684/0001493152-24-009684-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"44b1c587b750302e24b56b4766d126a415e8b1f3","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-12-29T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-06-24","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-12-26","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Imunon, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"December 26, 2023, Imunon, Inc. (“the Company”) received a letter from the staff (the “Staff”) of The Nasdaq\nStock Market LLC (“Nasdaq”) providing notification that, for the previous 30 consecutive business days, the bid price for\nthe Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital\nMarket under Nasdaq Listing Rule 5550(a)(2). Nasdaq’s\nnotice has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market, which continues to trade\nunder the symbol “IMNN”. In\naccordance with Nasdaq Listi","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-046587","anchor_url":"https://secwatch.observer/filing/0001493152-23-046587#claim-44b1c587b750302e24b56b4766d126a415e8b1f3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223046587/0001493152-23-046587-index.htm"},{"fact_type":"executive_change","fact_key":"8dd5579bfb","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-12-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-12-11","interim":false,"role":"Executive Vice President and Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dr. Sébastien Hazard was appointed as Executive Vice President and Chief Medical Officer at Imunon, Inc..","evidence_excerpt":"On December 7, 2023, Imunon, Inc. (the “Company”) appointed Dr. Sébastien Hazard to the positions of Executive Vice President and Chief Medical Officer of the Company, effective as of December 11, 2023.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-23-044323","anchor_url":"https://secwatch.observer/filing/0001493152-23-044323#claim-8dd5579bfb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223044323/0001493152-23-044323-index.htm"},{"fact_type":"earnings_release","fact_key":"06a41a8e1abed0a38a9f843b37e4632a34497504","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-11-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three and nine months ended September 30, 2023","report_date":"2023-11-14","result_type":"reported_results","revenue_text":null},"claim":"Imunon, Inc. reported financial results for the three and nine months ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, Imunon, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-040802","anchor_url":"https://secwatch.observer/filing/0001493152-23-040802#claim-06a41a8e1abed0a38a9f843b37e4632a34497504","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223040802/0001493152-23-040802-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5fe4cdc2eaad35171c58419f28b41382ec3a0ec5","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approve amendment to the 2018 Stock Incentive Plan (increase share limit to 1,970,000 shares)","proposal_type":"equity_plan","results":[{"broker_non_votes":"1,969,160","subject":null,"votes_abstain":"60,483","votes_against":"682,773","votes_for":"1,265,154","votes_withheld":null}]},"claim":"Imunon, Inc. shareholders approved Approve amendment to the 2018 Stock Incentive Plan (increase share limit to 1,970,000 shares).","evidence_excerpt":"The proposal to approve an amendment to the Stock Plan was approved based on the following votes: For Against Abstain Broker Non-Votes 1,265,154 682,773 60,483 1,969,160","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-021447","anchor_url":"https://secwatch.observer/filing/0001493152-23-021447#claim-5fe4cdc2eaad35171c58419f28b41382ec3a0ec5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223021447/0001493152-23-021447-index.htm"},{"fact_type":"shareholder_vote","fact_key":"07519844fd6ee00e4da6c2a0c9c86b9d7f8e9d42","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Advisory vote on frequency of future advisory votes on executive compensation","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"1,969,160","subject":null,"votes_abstain":"58,332","votes_against":"66,870","votes_for":"1,230,351","votes_withheld":null}]},"claim":"Imunon, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation.","evidence_excerpt":"The proposal to approve, on an advisory basis, the frequency by which future advisory votes on executive compensation will occur was approved for every year based upon the following votes: 1 Year 2 Year 3 Year Abstain Broker Non-Votes 1,230,351 66,870 652,857 58,332 1,969,160","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-021447","anchor_url":"https://secwatch.observer/filing/0001493152-23-021447#claim-07519844fd6ee00e4da6c2a0c9c86b9d7f8e9d42","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223021447/0001493152-23-021447-index.htm"},{"fact_type":"shareholder_vote","fact_key":"32e7da691386c670d5df6dad73b967724fb72f2d","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Advisory vote on 2022 compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"1,969,160","subject":null,"votes_abstain":"316,105","votes_against":"244,474","votes_for":"1,447,831","votes_withheld":null}]},"claim":"Imunon, Inc. shareholders approved Advisory vote on 2022 compensation of named executive officers.","evidence_excerpt":"The proposal to approve, on an advisory basis, the 2022 compensation of the Company’s named executive officers (“Say-on-Pay”), was approved based upon the following votes: For Against Abstain Broker Non-Votes 1,447,831 244,474 316,105 1,969,160","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-021447","anchor_url":"https://secwatch.observer/filing/0001493152-23-021447#claim-32e7da691386c670d5df6dad73b967724fb72f2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223021447/0001493152-23-021447-index.htm"},{"fact_type":"shareholder_vote","fact_key":"48fb6928da0a0c0e103b888c71e39e0f2d58bf5e","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-31","outcome":"passed","proposal_text":"Ratify the appointment of WithumSmith+ Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"47,280","votes_against":"177,797","votes_for":"3,752,493","votes_withheld":null}]},"claim":"Imunon, Inc. shareholders approved Ratify the appointment of WithumSmith+ Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting.","evidence_excerpt":"The proposal, by the audit committee of the board of directors of the Company, to ratify the appointment of WithumSmith+ Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2023, as described in the proxy materials, was approved by the stockholders. The voting results were the following: For Against Abstain 3,752,493 177,797 47,280","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-021447","anchor_url":"https://secwatch.observer/filing/0001493152-23-021447#claim-48fb6928da0a0c0e103b888c71e39e0f2d58bf5e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223021447/0001493152-23-021447-index.htm"},{"fact_type":"shareholder_vote","fact_key":"cdac5d069c031758ea485d692d89298d0444de3e","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-06-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"1,969,160","subject":"Frederick J. Fritz","votes_abstain":null,"votes_against":null,"votes_for":"1,384,165","votes_withheld":"624,245"},{"broker_non_votes":"1,969,160","subject":"Christine A. Pellizzari","votes_abstain":null,"votes_against":null,"votes_for":"1,833,554","votes_withheld":"174,856"}]},"claim":"Imunon, Inc. shareholders approved Election of Directors.","evidence_excerpt":"Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the Board of Directors until the 2026 Annual Meeting of Stockholders. Nominee For Withheld Broker Non-Votes Frederick J. Fritz 1,384,165 624,245 1,969,160 Christine A. Pellizzari 1,833,554 174,856 1,969,160","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-021447","anchor_url":"https://secwatch.observer/filing/0001493152-23-021447#claim-cdac5d069c031758ea485d692d89298d0444de3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223021447/0001493152-23-021447-index.htm"},{"fact_type":"executive_change","fact_key":"379dda205d","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"routine","effective_date":"2023-06-14","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Augustine Chow retired as Class I Director at Imunon, Inc..","evidence_excerpt":"On June 14, 2023, Augustine Chow, Ph.D., a Class I member of the Board of Directors (the “Board”) of Imunon, Inc. (the “Registrant”), retired from the Registrant’s Board upon conclusion of the 2023 Annual Meeting of Stockholders (the “Meeting”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-021229","anchor_url":"https://secwatch.observer/filing/0001493152-23-021229#claim-379dda205d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223021229/0001493152-23-021229-index.htm"},{"fact_type":"earnings_release","fact_key":"226493829d7d4c1cc8ebab388d68dd71380a732b","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-05-11T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months ended March 31, 2023","report_date":"2023-05-11","result_type":"reported_results","revenue_text":null},"claim":"Imunon, Inc. reported financial results for the three months ended March 31, 2023.","evidence_excerpt":"IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three months ended March 31, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-016286","anchor_url":"https://secwatch.observer/filing/0001493152-23-016286#claim-226493829d7d4c1cc8ebab388d68dd71380a732b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223016286/0001493152-23-016286-index.htm"},{"fact_type":"earnings_release","fact_key":"204733deaa712c23a8429b9c187de13b3edd6507","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2022","report_date":"2023-03-30","result_type":"reported_results","revenue_text":null},"claim":"Imunon, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, Imunon, Inc. issued a press release reporting its financial results for the year ended December 31, 2022.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001493152-23-009599","anchor_url":"https://secwatch.observer/filing/0001493152-23-009599#claim-204733deaa712c23a8429b9c187de13b3edd6507","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223009599/0001493152-23-009599-index.htm"},{"fact_type":"governance_change","fact_key":"fec6b0718ded8c8162407ce21a82edf1239ac1a7","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-03-24T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-03-22","item_codes_triggered":["5.03"],"summary_text":"Filed a Restated Certificate of Incorporation to restate and integrate previous amendments"},"claim":"Imunon, Inc.: Filed a Restated Certificate of Incorporation to restate and integrate previous amendments (effective 2023-03-22).","evidence_excerpt":"On March 22, 2023, Imunon, Inc. filed a Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to restate and integrate the provisions of the Restated Certificate of Incorporation, as previously amended or supplemented.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-008888","anchor_url":"https://secwatch.observer/filing/0001493152-23-008888#claim-fec6b0718ded8c8162407ce21a82edf1239ac1a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223008888/0001493152-23-008888-index.htm"},{"fact_type":"executive_change","fact_key":"9b50a5c397","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-02-10T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2023-02-28","interim":false,"role":"Executive Vice President and Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Nicholas Borys departed as Executive Vice President and Chief Medical Officer at Imunon, Inc..","evidence_excerpt":"On February 10, 2023, Imunon, Inc., a Delaware corporation (“Imunon”), announced that Nicholas Borys, its Executive Vice President and Chief Medical Officer, would separate from Imunon effective as of February 28, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-004311","anchor_url":"https://secwatch.observer/filing/0001493152-23-004311#claim-9b50a5c397","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223004311/0001493152-23-004311-index.htm"},{"fact_type":"executive_change","fact_key":"136045d959","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2023-01-03T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2022-12-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robert W. Hooper retired as Director at Imunon, Inc..","evidence_excerpt":"On December 31, 2022, Robert W. Hooper, a Class II member of the Board of Directors (the “Board”) of Imunon, Inc. (the “Registrant”), announced that he has decided to retire from the Registrant’s Board effective December 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-000132","anchor_url":"https://secwatch.observer/filing/0001493152-23-000132#claim-136045d959","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223000132/0001493152-23-000132-index.htm"},{"fact_type":"earnings_release","fact_key":"212ab0d44b552d682aa4815160655df64908f47f","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three-month and nine-month periods ended September 30, 2022","report_date":"2022-11-14","result_type":"reported_results","revenue_text":null},"claim":"Imunon, Inc. reported financial results for the three-month and nine-month periods ended September 30, 2022.","evidence_excerpt":"IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J. (November 14, 2022) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three-month and nine-month periods ended September 30, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-031636","anchor_url":"https://secwatch.observer/filing/0001493152-22-031636#claim-212ab0d44b552d682aa4815160655df64908f47f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315222031636/0001493152-22-031636-index.htm"},{"fact_type":"executive_change","fact_key":"63319695ed","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2022-10-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-09-29","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James E. Dentzer was appointed as Class II Director at Imunon, Inc..","evidence_excerpt":"On October 3, 2022, Imunon, Inc. (the “Company”) announced that the Board of Directors (the “Board”) appointed James E. Dentzer to the Board as a Class II Director effective September 29, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-027459","anchor_url":"https://secwatch.observer/filing/0001493152-22-027459#claim-63319695ed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315222027459/0001493152-22-027459-index.htm"},{"fact_type":"executive_change","fact_key":"52dc02eea3","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2022-07-19T23:59:59+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-07-18","interim":false,"role":"Executive Chairman","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Michael H. Tardugno changed role as Executive Chairman at Imunon, Inc..","evidence_excerpt":"Michael H. Tardugno, the Company’s current Chairman, President and Chief Executive Officer, will transition from his current role to the position of Executive Chairman of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-019765","anchor_url":"https://secwatch.observer/filing/0001493152-22-019765#claim-52dc02eea3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315222019765/0001493152-22-019765-index.htm"},{"fact_type":"executive_change","fact_key":"606f547699","cik":749647,"ticker":"IMNN","company_name":"Imunon, Inc.","filed_at":"2021-12-30T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2021-12-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andreas Voss retired as Director at Imunon, Inc..","evidence_excerpt":"Dr. Andreas Voss, a Class III member of the Board of Directors (the “Board”) will retire from the Company’s Board effective December 31, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-21-032854","anchor_url":"https://secwatch.observer/filing/0001493152-21-032854#claim-606f547699","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315221032854/0001493152-21-032854-index.htm"}]}